Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 49, 2020 - Issue 1
Submit an article Journal homepage
196
Views
7
CrossRef citations to date
0
Altmetric
Letters

Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma

K ShikanoDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, JapanCorrespondence[email protected]
,
K KanekoDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
,
K KaburakiDivision of Respiratory Medicine, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
,
K IsobeDivision of Respiratory Medicine, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
,
K KawabeDivision of Neurology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
,
S HommaDivision of Respiratory Medicine, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
,
S KawaiDepartment of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan
&
T NankiDivision of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
 show all
Pages 82-83 | Accepted 13 Mar 2019, Published online: 28 May 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma." Scandinavian Journal of Rheumatology, 49(1), pp. 82–83

Disclosure statement

TN received grant/research support from Bristol-Myers KK and Ono Pharmaceutical Co. Ltd, a consultant fee from Ono Pharmaceutical Co. Ltd, and speaker fees from Bristol-Myers KK and Ono Pharmaceutical Co. Ltd. SK has received research grants from Ono Pharmaceutical Co. Ltd, a manufacturer of nivolumab. All other authors have declared no conflicts of interest.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 171.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.